---
title: "Descartes-08 in Generalized myasthenia gravis: Neonatal fc receptor blockers"
description: "Formulary evidence on Descartes-08 in Generalized myasthenia gravis: Neonatal fc receptor blockers. Topics: Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance; Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials; Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing; Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial; 7 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description/neonatal-fc-receptor-blockers"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Descartes-08 in Generalized myasthenia gravis: Neonatal fc receptor blockers

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Neonatal Fc Receptor Blockers

<a id="topic-2.2.2.1.7-1"></a>

### Mechanism, onset, and comparative effect of FcRn blockers: Nordic guidance

> “Monoclonal antibodies directed at the FcRn receptor's binding site for IgG block recycling and lead to a 60%–70% reduction in circulating IgG.”
> “The treatment can be tailored according to the disease state; new treatment cycles can be administered with signs of symptom worsening or according to a fixed schedule.”
> “The number of treatment responders and the magnitude of the treatment response for FcRn blockers and complement inhibitors seem to be similar. No prospective and controlled head‐to‐head studies have been undertaken.”

Source: [Gilhus et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11236053/)

<a id="topic-2.2.2.1.7-2"></a>

### Efgartigimod intravenous: FDA-labeled indication, dosing, and pivotal trials

> “VYVGART is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).”
> “The recommended dosage of VYVGART is 10 mg/kg administered as an intravenous infusion over one hour once weekly for 4 weeks.”
> “A statistically significant difference favoring VYVGART was observed in the MG-ADL responder rate during the first treatment cycle (67.7% in the VYVGART-treated group vs 29.7% in the placebo- treated group [p <0.0001]).”
> “A statistically significant difference favoring VYVGART was observed (LS mean difference [95% CI] = - 1.46 [-2.50 to -0.41]; p-value = 0.0068).”

Source: [Vyvgart prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761195s016lbl.pdf)

<a id="topic-2.2.2.1.7-3"></a>

### Efgartigimod alfa and hyaluronidase subcutaneous: FDA-labeled indication and dosing

> “VYVGART HYTRULO is indicated for the treatment of adult patients with: • generalized myasthenia gravis (gMG)”
> “The recommended dosage of VYVGART HYTRULO prefilled syringe is 1,000 mg / 10,000 units (1,000 mg efgartigimod alfa and 10,000 units hyaluronidase) administered subcutaneously over approximately 20 seconds to 30 seconds in cycles of once weekly injections for 4 weeks.”
> “VYVGART HYTRULO prefilled syringe may be administered by patients and/or caregivers after proper instruction in subcutaneous injection technique”
> “In Study 3, VYVGART HYTRULO demonstrated a comparable pharmacodynamic effect as compared to the efgartigimod alfa-fcab intravenous formulation, which established the efficacy of VYVGART HYTRULO”

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Rozanolixizumab: FDA-labeled indication, dosing, and pivotal trial

> “RYSTIGGO (rozanolixizumab-noli) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “Administer the recommended dosage as a subcutaneous infusion using an infusion pump at a rate of up to 20 mL/hour once weekly for 6 weeks.”
> “A statistically significant difference favoring RYSTIGGO was observed in the MG-ADL total score change from baseline [-3.4 points in RYSTIGGO-treated group at either dose vs -0.8 points in the placebo-treated group (p<0.001)].”

Source: [Rystiggo prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761286s007lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Nipocalimab: FDA-labeled indication, dosing, and pivotal trial

> “generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti- muscle-specific tyrosine kinase (MuSK) antibody positive.”
> “30 mg/kg administered once via intravenous infusion over at least 30 minutes. Two weeks after the initial dose administer a maintenance dose of 15 mg/kg via intravenous infusion over at least 15 minutes. Continue the maintenance dose every two weeks thereafter.”
> “In gMG Study 1, a total of 196 patients were randomized 1:1 to receive IMAAVY (n=98) or placebo (n=98).”
> “Primary Endpoint MG-ADL Total Score1 -4.7 (0.33) -3.3 (0.34) -1.5 (-2.4, -0.5) 0.002”

Source: [Imaavy prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761430s002lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

### Incomplete response to FcRn inhibition

> “Trials of efgartigimod and rozanolixizumab in MG reported a subset of patients who responded poorly despite a reduction in circulating antibodies.”

Source: [Kaminski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11178544/)

<a id="topic-2.2.2.1.7-7"></a>

### Efgartigimod intravenous: ADAPT phase 3 trial, AChR antibody-positive modified intention-to-treat population, first treatment cycle

> “The primary endpoint was proportion of acetylcholine receptor antibody-positive patients who were MG-ADL responders (≥2-point MG-ADL improvement sustained for ≥4 weeks) in the first treatment cycle.”
> “Between Sept 5, 2018, and Nov 26, 2019, 167 patients (84 in the efgartigimod group and 83 in the placebo group) were enrolled, randomly assigned, and treated. 129 (77%) were acetylcholine receptor antibody-positive. Of these patients, more of those in the efgartigimod group were MG-ADL responders (44 [68%] of 65) in cycle 1 than in the placebo group (19 [30%] of 64), with an odds ratio of 4·95 (95% CI 2·21-11·53, p<0·0001).”
> “Four (5%) efgartigimod-treated patients and seven (8%) patients in the placebo group had a serious adverse event.”

Source: [Howard et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34146511/)

<a id="topic-2.2.2.1.7-8"></a>

### Efgartigimod alfa and hyaluronidase subcutaneous: ADAPT-SC noninferiority trial, total IgG reduction at week 4

> “The ADAPT-SC primary endpoint was met. The LSM estimate of percentage change from baseline in total IgG level at week 4 was −66.4% for the efgartigimod PH20 SC arm vs −62.2% for the efgartigimod IV arm (Table 2), giving a LSM difference of −4.2% (95% CI, −7.73 to −0.66).”
> “Analysis of AChR-Ab+ participants in the efgartigimod PH20 SC and efgartigimod IV arms demonstrated similar percentages of MG-ADL responders (efgartigimod PH20 SC: 71.1%; efgartigimod IV: 71.7%)”

Source: [Howard et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11579873/)

<a id="topic-2.2.2.1.7-9"></a>

### Rozanolixizumab: MycarinG phase 3 trial, intention-to-treat population, day 43

> “Between June 3, 2019, and June 30, 2021, 300 patients were assessed for eligibility, of whom 200 were enrolled. 66 (33%) were randomly assigned to rozanolixizumab 7 mg/kg, 67 (34%) to rozanolixizumab 10 mg/kg, and 67 (34%) to placebo.”
> “Reductions in MG-ADL score from baseline to day 43 were greater in the rozanolixizumab 7 mg/kg group (least-squares mean change -3·37 [SE 0·49]) and in the rozanolixizumab 10 mg/kg group (-3·40 [0·49]) than with placebo (-0·78 [0·49]; for 7 mg/kg, least-squares mean difference -2·59 [95% CI -4·09 to -1·25], p<0·0001; for 10 mg/kg, -2·62 [-3·99 to -1·16], p<0·0001).”
> “The most frequent TEAEs were headache (29 [45%] patients in the rozanolixizumab 7 mg/kg group, 26 [38%] in the rozanolixizumab 10 mg/kg group, and 13 [19%] in the placebo group), diarrhoea (16 [25%], 11 [16%], and nine [13%]), and pyrexia (eight [13%], 14 [20%], and one [1%]).”

Source: [Bril et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37059507/)

<a id="topic-2.2.2.1.7-10"></a>

### Nipocalimab: Vivacity-MG3 phase 3 trial, antibody-positive intention-to-treat population, weeks 22 to 24

> “Between July 15, 2021, and Nov 17, 2023, 199 patients were enrolled, and 196 patients received study drug (98 in the nipocalimab group and 98 in the placebo group); of these, 153 (77 in the nipocalimab group and 76 in the placebo group) were antibody-positive.”
> “The least-squares mean change in MG-ADL score from baseline to weeks 22, 23, and 24 was -4·70 (SE 0·329) in the nipocalimab group versus -3·25 (0·335) in the placebo group (difference -1·45 [95% CI -2·38 to -0·52]; p=0·0024).”
> “Serious adverse events were reported for nine (9%) of 98 patients in the nipocalimab group and 14 (14%) of 98 patients in the placebo group, three of which had a fatal outcome (nipocalimab: myasthenic crisis; placebo: cardiac arrest and myocardial infarction).”

Source: [Antozzi et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39862879/)

<a id="topic-2.2.2.1.7-11"></a>

### FcRn inhibitor initiation, cycle timing, and IgG monitoring: German-Austrian expert recommendations

> “Recommendation (strong consensus): Add‐on therapy with FcRn‐I should be considered for patients with (highly) active gMG (including therapy‐refractory disease) who are positive for AChR‐ and MuSK‐autoantibodies.”
> “Recommendation (strong consensus): Timing of a new FcRn‐I cycle should be individualised.”
> “Recommendation (strong consensus): FcRn‐I therapy should be accompanied by monitoring of infections and IgG levels, particularly before initiation and, if needed, at the beginning and end of individual treatment cycles depending on the values obtained.”

Source: [Meisel et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13559022/)

## Related pages
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis.md)
- [Descartes-08 in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Descartes-08: Generalized myasthenia gravis](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/executive-summary.md)
- [Descartes-08 in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Descartes-08 in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/clinical-evidence.md)
- [Descartes-08 in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/economics.md)
- [Descartes-08 in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/descartes-08--generalized-myasthenia-gravis/references.md)
